# Phase III Double-blind, Placebo-controlled Study of AZD7442 for Post- Exposure Prophylaxis of COVID-19 in Adults

> **NCT04625972** · PHASE3 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 1131 (actual)

## Conditions studied

- COVID-19

## Interventions

- **DRUG:** AZD7442
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04625972
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-12-02
- **Primary completion:** 2021-04-07
- **Final completion:** 2022-07-25
- **Target enrollment:** 1131 (ACTUAL)
- **Last updated:** 2023-11-21

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04625972

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04625972, "Phase III Double-blind, Placebo-controlled Study of AZD7442 for Post- Exposure Prophylaxis of COVID-19 in Adults". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04625972. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*